Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational

Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation

ClinicalTrials.gov ID: NCT05309382

Public ClinicalTrials.gov record NCT05309382. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplant

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a prospective, multicenter observational, unblinded, longitudinal cohort study. Subjects will be enrolled into the study prior to or at the time of heart transplantation. All subjects will follow the center's standard of care surveillance schedule. Blood samples will be collected for Prospera testing at the time any surveillance or for-cause testing, which may include endomyocardial biopsy (EMB), echocardiography or other cardiac imaging studies, and/or molecular testing, is performed.

Study identification

NCT ID
NCT05309382
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
Natera, Inc.
Industry
Enrollment
147 participants

Conditions and interventions

Interventions

Diagnostic Test

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 11, 2022
Primary completion
Oct 1, 2024
Completion
Oct 1, 2024
Last update posted
Oct 28, 2024

2022 – 2024

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
Cedars-Sinai Medical Center Los Angeles California 90048
University of California, San Diego San Diego California 92103
Mayo Clinic Jacksonville Florida 32224
Northwestern Memorial Hospital Chicago Illinois 60611
Brigham and Women's Hospital Boston Massachusetts 02115
Cleveland Clinic Foundation Cleveland Ohio 44195
Vanderbilt University Medical Center Nashville Tennessee 37332
University of Utah Salt Lake City Utah 84112
Inova Heart and Vascular Institute Falls Church Virginia 22042

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05309382, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 28, 2024 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05309382 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →